By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Research findings on Biotechnology are discussed in a new report. According to news reporting from Uttar Pradesh, India, by NewsRx journalists, research stated, "Targeting of tumor metabolism is emerging as a novel therapeutic strategy against cancer. Dichloroacetate (DCA), an inhibitor of pyruvate dehydrogenase kinase (PDK), has been shown to exert a potent tumoricidal action against a variety of tumor cells."
The news correspondents obtained a quote from the research from Banaras Hindu University, "The main mode of its antineoplastic action implicates a shift of glycolysis to oxidative metabolism of glucose, leading to generation of cytotoxic reactive oxygen intermediates. However, the effect of DCA on tumor microenvironment, which in turn regulates tumor cell survival; remains speculative to a large extent It is also unclear if DCA can exert any modulatory effect on the process of hematopoiesis, which is in a compromised state in tumor-bearing hosts undergoing chemotherapy. In view of these lacunas, the present study was undertaken to investigate the so far unexplored aspects with respect to the molecular mechanisms of DCA-dependent tumor growth retardation and chemosensitization. BALB/c mice were transplanted with Dalton's lymphoma (DL) cells, a T cell lymphoma of spontaneous origin, followed by administration of DCA with or without cisplatin. DCA-dependent tumor regression and chemosensitization to cisplatin was found to be associated with altered repertoire of key cell survival regulatory molecules, modulated glucose metabolism, accompanying reconstituted tumor microenvironment with respect to pH homeostasis, cytokine balance and alternatively activated TAM. Moreover, DCA administration also led to an alteration in the MDR phenotype of tumor cells and myelopoietic differentiation of macrophages."
According to the news reporters, the research concluded: "The findings of this study shed a new light with respect to some of the novel mechanisms underlying the antitumor action of DCA and thus may have immense clinical applications."
For more information on this research see: Antitumor and chemosensitizing action of dichloroacetate implicates modulation of tumor microenvironment: A role of reorganized glucose metabolism, cell survival regulation and macrophage differentiation. Toxicology and Applied Pharmacology, 2013;273(1):196-208. Toxicology and Applied Pharmacology can be contacted at: Academic Press Inc Elsevier Science, 525 B St, Ste 1900, San Diego, CA 92101-4495, USA. (Elsevier - www.elsevier.com; Toxicology and Applied Pharmacology - www.elsevier.com/wps/product/cws_home/622951)
Our news journalists report that additional information may be obtained by contacting A. Kumar, Banaras Hindu Univ, Sch Biotechnol, Varanasi 221005, Uttar Pradesh, India. Additional authors for this research include S. Kant and S.M. Singh (see also Biotechnology).
Keywords for this news article include: Asia, Antineoplastics, Biotechnology, Pharmaceuticals, India, Drugs, Cisplatin, Immunology, Metabolism, Macrophages, Acetic Acids, Chemotherapy, Uttar Pradesh, Myeloid Cells, Dichloroacetate, Carboxylic Acids, Alkylating Agents, Lymphoma Gene Therapy, Connective Tissue Cells, Chlorinated Hydrocarbons
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC